Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation

• Published in: American journal of physiology: Gastrointestinal and liver physiology Vol. 294; no. 6; pp. G1354 - G1361
• Main Authors: Kekuda, Ramesh, Saha, Prosenjit, Sundaram, Uma
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.06.2008
• Subjects: Animals; Binding sites; Cells, Cultured; Chronic Disease; Cloning; Enteritis - metabolism; Gastrointestinal diseases; Gene expression; Gene Expression Regulation; Hepatocyte Nuclear Factor 1 - metabolism; Immunoglobulins - metabolism; Intestines - metabolism; Male; Proteins; Rabbits; Sodium-Glucose Transporter 1 - metabolism; Transcription Factors - metabolism
• ISSN: 0193-1857; 1522-1547
• DOI: 10.1152/ajpgi.00080.2008

In a rabbit model of chronic intestinal inflammation, we previously demonstrated that the activity of Na-glucose cotransporter (SGLT1), SLC5A1, is inhibited. This inhibition is secondary to a decrease in the number of cotransporters, indicating that the regulation of SGLT1 during chronic inflammation is at the level of transcription. However, the regulation of SGLT1 expression and the transcription factors involved in the regulation are not yet known. In this report, we describe the cloning and characterization of rabbit SGLT1 promoter and the identification of transcription factors affected in villus cells during chronic intestinal inflammation. The promoter sequence for SGLT1 gene was identified by using the publicly available rabbit genomic sequence. Even though rabbit SGLT1 promoter did not have considerable overall homology with other mammalian SGLT1 promoters, two specificity protein 1 (Sp1) and a hepatocyte nuclear factor 1 (HNF1) binding sites were highly conserved among the species. Rabbit SGLT1 cDNA was encoded by 15 exons. Minimal promoter region determination showed that 196 nucleotides upstream of the transcription start site were sufficient for optimal promoter activity. This region encompassed two transcription factor binding sites, Sp1 and HNF1. For maximal SGLT1 promoter activity, these two transcription factor binding sites were essential, and their effect was synergistic, indicating that two separate regulatory pathways might be involved in their regulation. Using mobility shift assays, we further demonstrated that the binding of both Sp1 and HNF1 transcription factors to SGLT1 promoter regions were affected during chronic intestinal inflammation. Thus this report demonstrates that Sp1 and HNF1 transcription factors act in concert to regulate SGLT1 transcription in the chronically inflamed intestine.